Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

Related Keywords

San Diego ,California ,United States ,American ,Syed Rizvi ,Rajesh Belani ,Bhagirathbhai Dholaria ,Poseida Therapeutics Inc ,Vanderbilt Ingram Cancer Center ,Drug Administration ,Prnewswire Poseida Therapeutics Inc ,Nasdaq ,Clinical Development ,American Association For Cancer Research ,Linkedin ,American Association ,Cancer Research ,Annual Meeting ,Associate Professor ,Chief Medical Officer ,Subgroup Data ,Optimizing Lymphodepletion ,Solid Tumors Treated ,Investigational Allogeneic ,B Cell Maturation Antigen ,Relapsed Refractory Multiple Myeloma ,Patients Following Progression ,Poseida Therapeutics ,Clinical Trials ,Multiple Myeloma Patients ,Achieve Adequate Lymphodepletion Necessary ,Enable Allogeneic ,Translational Medicine ,Orphan Drug Designation ,Site Specific Gene Editing System ,Booster Molecule ,Nc ,